pSivida Corp. has acquired the specialty biopharmaceutical company Icon Bioscience Inc. and will rebrand as EyePoint Pharmaceuticals, according to pSivida CEO Nancy Lurker, who spoke with Healio.com/OSN.
Icon’s lead product candidate Dexycu (dexamethasone intraocular suspension 9%), a long-acting intraocular product approved for postoperative inflammation, was approved by the FDA on Feb. 9. Administered at the end of cataract surgery, Dexycu uses Icon’s Verisome drug-delivery platform, which allows for a single injection that releases product over time, according to a press
Uncategorized